



Ref: JSTL/BOD/BSE/2022-23/Feb23

Date: February 08, 2023

**To,
BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, Phiroze Jeejeebhoy
Towers, Dalal Street, Fort,
Mumbai- 400001
(BSE Scrip Code: 538837)**

Dear Sir/Madam,

Sub: Copy of Unaudited Financial Results for the Quarter and Nine Months
Ended 31st December 2022

Ref: Scrip code: 538837

Unit: Jeevan Scientific Technology Limited

Please find enclosed herewith a Copy of Unaudited Financial Results for the Quarter and Nine Months Ended 31st December, 2022 which were taken on record by the Board of Directors at their Meeting held on 08th February, 2023.

This is for your information and records,

Thanking you,
Yours truly,

For JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

**K. KRISHNA KISHORE
VICE CHAIRMAN & MANAGING DIRECTOR
(DIN: 00876539)**

Encl. As above

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED
Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2022

Rupees in Lakhs

Sl.No	Particulars	Quarter Ended			Nine Months Ended			Year Ended
		31-12-2022 Un Audited	30-09-2022 Un Audited	31-12-2021 Un Audited	31-12-2022 Un Audited	31-12-2021 Un Audited	31-03-2022 Audited	
1	Income							
	(a) Revenue From Operations	995.17	797.33	1606.55	2825.28	4590.41	5655.49	
	(b) Other Income	27.78	30.70	38.73	79.95	79.34	590.98	
	Total Income	1,022.95	828.03	1,645.28	2,905.23	4,669.75	6,246.47	
2	Expenses							
	(a) Cost of Material Consumed	72.53	58.45	90.73	171.90	317.83	369.43	
	(b) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-	-	129.58	-	244.62	369.93	
	(c) Employee benefit expense	400.59	362.88	317.30	1065.32	973.56	1502.38	
	(d) Finance Cost	20.69	21.81	21.89	69.69	76.38	95.83	
	(e) Depreciation and Amortisation expense	133.97	126.13	98.08	365.40	296.48	367.93	
	(f) Other Expenses	375.94	417.42	441.87	1354.90	1288.71	1706.07	
	Total Expenses	1,003.72	986.69	1,099.45	3,027.21	3,197.58	4,411.57	
3	Profit before exceptional items and Tax	19.23	(158.66)	545.83	(121.98)	1,472.17	1,834.90	
4	Add(+) / Less(-) Exceptional Items	-	-	-	-	-	-	
5	Profit/ (Loss) before Tax	19.23	(158.66)	545.83	(121.98)	1,472.17	1,834.90	
6	Tax Expenses							
	Current Tax	-	-	164.11	-	446.42	497.93	
	Deferred Tax	13.78	(39.55)	0.66	(46.63)	14.77	110.66	
7	Profit(Loss) for the period/year	5.45	(119.11)	381.06	(75.35)	1,010.98	1,226.31	
8	Other Comprehensive Income							
	A (i) Items that will not be reclassified to profit or loss	0.88	(7.46)	1.11	(5.71)	2.37	21.03	
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-	
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-	
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	
	Comprehensive Income for the period /year	0.88	(7.46)	1.11	(5.71)	2.37	21.03	
9	Total Comprehensive Income for the period /year	6.33	(126.57)	382.17	(81.06)	1,013.35	1,247.34	
10	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	1,530.15	1,530.15	1,530.15	1,530.15	1,530.15	1,530.15	
11	Other equity excluding revaluation reserve	-	-	-	-	-	3528.16	
12	Earnings per Equity share (for continuing operations)							
	a) Basic (Amount in Rupees)	0.04	(0.83)	2.50	(0.53)	6.62	8.15	
	b) Diluted (Amount in Rupees)	0.04	(0.83)	2.50	(0.53)	6.62	8.15	



[Signature]

[Signature]

Notes to the Un Audited Financial Results


1. The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules 2016.
2. The operations of the company has only one segment namely "Clinical "Research Services. Hence segmental reporting as per Ind AS 108 is not made.
3. Employee benefit expenses for Nine Months ending 31-12-2022 includes Rs. 161.29 Lakhs towards ESOP Scheme 2016 provided as per " Ind AS 102 - Share Based Payments"
4. "The Company continues to monitor the impact of Covid-19 on its business, including its impact on customers, supply-chain, employees and logistics.
5. Figures for the previous periods have been rearranged/ reclassified wherever necessary to conform to the current period presentation
6. The above Unaudited results have been reviewed by the Audit Committee at its meeting held on 08.02.2023 and approved by the Board of Directors of the Company on the same date. The results are also subjected to Limited Review by the Company's Statutory Auditors.

for Jeevan Scientific Technology Limited


K. Jeevan Krishna
Executive Director & CFO
(DIN: 08207809)


K. Krishna Kishore
Vice Chairman & Managing Director
(DIN: 00876539)

Place: Hyderabad
Date: 08.02.2023





Ref: JSTL/BOD/BSE/2022-23/Feb23

Date: February 08, 2023

**To,
BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, Phiroze Jeejeebhoy
Towers, Dalal Street, Fort,
Mumbai- 400001
(BSE Scrip Code: 538837)**

Dear Sir/Madam,

Sub: Limited Review report of the Unaudited Financial Results for the Quarter and
Nine Months Ended 31st December 2022

Ref: Scrip code: 538837

Unit: Jeevan Scientific Technology Limited

We are herewith enclosing the Limited Review Report issued by our Statutory Auditors relating to the Unaudited Financial Results for the Quarter and Nine Months Ended 31st December 2022 which were taken on record by the Board of Directors at their Meeting held on the 08th February, 2023.

This is for your information and records,

Thanking you,

Yours truly,

For JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

**K. KRISHNA KISHORE
VICE CHAIRMAN & MANAGING DIRECTOR
(DIN: 00876539)**


Encl. As above



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM
FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
JEEVAN SCIENTIFIC TECHNOLOGY LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of JEEVAN SCIENTIFIC TECHNOLOGY LIMITED ("the Company"), for the quarter and Nine Months ended December 31, 2022 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PAVULURI & Co
Chartered Accountants
Firm Reg. No: 012194S

CA N RAJESH
Partner
M. No: 223169



Place : Hyderabad
Date :08/02/2023

UDIN # **23223169BGVJQB5792**